Akari initiates GLP toxicology for ADC AKTX-101
Akari Therapeutics started GLP studies for AKTX-101 and secured $5.7M in cash, advancing its novel PH1 payload towards clinical trials.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed